Increased Demand, Fast Track Designations, and Strong Sales Boost Revenue Growth - Research Report on Alexion, Baxter International, Align Technology, Transition, and OPKO

NEW YORK, July 23, 2013 /PRNewswire/ --

Today, Analysts' Corner announced new research reports highlighting Alexion Pharmaceuticals Inc. (NASDAQ: ALXN), Baxter International Inc. (NYSE: BAX), Align Technology, Inc. (NASDAQ: ALGN), Transition Therapeutics Inc. (NASDAQ: TTHI), and OPKO Health Inc. (NYSE: OPK). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.

Alexion Pharmaceuticals Inc. Research Report

On July 16, 2013, Alexion Pharmaceuticals Inc. (Alexion) announced that the Company's first-in-class terminal complement inhibitor, Soliris (eculizumab) has received a positive opinion for orphan medicinal product designation from the Committee for Orphan Medical Products (COMP) of the European Medicines Agency (EMA) for the treatment of neuromyelitis optica (NMO), a life-threatening, ultra-rare neurological disorder. An orphan medicinal product status, granted by the European Commission, provides incentives to develop medicinal products to treat, prevent, or diagnose diseases or conditions that affect no more than five in 10,000 persons in the EU. The proposed status would provide Alexion with certain benefits and incentives, including a period of marketing exclusivity. According to the Company, the positive opinion of the COMP has now been forwarded to the European Commission for final approval and publication in the community register. The Full Research Report on Alexion Pharmaceuticals Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.analystscorner.com/r/full_research_report/4619_ALXN]

--

Baxter International Inc. Research Report

On July 18, 2013, Baxter International Inc. (Baxter International) announced its financial results for Q2 2013. Worldwide sales of the Company increased 3% YoY to $3.7 billion. According to the Company, BioScience sales rose 6% YoY on constant currency basis and 5% on actual basis to $1.6 billion, due to improved demand for the Company's hemophilia therapies, including ADVATE [Antihemophilic Factor (Recombinant) Plasma/Albumin-Free Method] and FEIBA (an inhibitor therapy) as well as accelerated growth of select plasma-based therapeutics and vaccines. The Company reported Medical Products sales of $2.0 billion, reflecting 1% growth, driven primarily by gains in peritoneal dialysis patients, as well as growth of certain injectable therapies and anesthesia products. Further, the Company reported net income of $590 million or $1.07 per diluted share compared to net income of $661 million or $1.19 per diluted share in Q2 2012. These results include after-tax special items totaling $49 million ($0.09 per diluted share) primarily for costs associated with Baxter's planned acquisition of Gambro AB. Q2 2013 results also included a net after-tax benefit from special items totaling $42 million of income ($0.07 per diluted share). The Full Research Report on Baxter International Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.analystscorner.com/r/full_research_report/163d_BAX]

--

Align Technology, Inc. Research Report

On July 18, 2013, Align Technology Inc. (Align Technology) reported its financial results for Q2 2013. Total net revenues increased 6.6% QoQ to $163.8 million, with Invisalign clear aligner revenues increasing 8.3% QoQ to $153.3 million. Net profit was $29.3 million or $0.36 per diluted share compared to net loss of $42 million or $0.52 per diluted share in Q1 2013 and net profit of $28.5 million or $0.34 in Q2 2012. Commenting on the results, Thomas M. Prescott, President and Chief Executive Officer of Align Technology, said, "Strong second quarter results were driven by higher Invisalign volumes and ASPs, with sequential growth across all customer channels." The Full Research Report on Align Technology, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:  [http://www.analystscorner.com/r/full_research_report/69b3_ALGN]

--

Transition Therapeutics Inc. Research Report

On July 17, 2013, Transition Therapeutics Inc. (Transition) announced that the US Food and Drug Administration (FDA) granted Fast Track Designation to the development program for ELND005, which was submitted for the treatment of Neuropsychiatric Symptoms (NPS) in Alzheimer's disease (AD). According to the Company, ELND005 is an orally bioavailable small molecule that is being investigated by Transition's licensing partner, Elan Corporation plc (Elan), for multiple neuropsychiatric indications on the basis of its proposed dual mechanism of action, which includes β-amyloid anti-aggregation and regulation of brain myo-inositol levels. Elan will be responsible for all development and commercialization activities as well as costs of ELND005. The Full Research Report on Transition Therapeutics Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.analystscorner.com/r/full_research_report/09eb_TTHI]

--

OPKO Health Inc. Research Report

On July 16, 2013, OPKO Health Inc. (OPKO) announced the appointment of David Okrongly, Ph.D. as the President of the Company's Diagnostics Business Unit. According to OPKO, Dr. Okrongly brings extensive experience developing and commercializing advanced diagnostic platforms. Prior to his involvement with OPKO, Dr. Okrongly served as the Chief Operating Officer of Exosome Diagnostics, Inc., where he was responsible for establishing product, platform, and regulatory strategy for the Company's proprietary technology for purifying RNA derivatives from exosomes. Phillip Frost, M.D., Chairman and Chief Executive Officer of OPKO, said, "David's profound industry knowledge will be invaluable as we near the U.S. commercial launch for our 4Kscore prostate cancer diagnostic test, advance the development of our point of care diagnostic platform, and continue to execute our strategy of establishing industry-leading positions in large and rapidly growing medical markets." The Full Research Report on OPKO Health Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.analystscorner.com/r/full_research_report/cd43_OPK]

----

EDITOR NOTES:

1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.
2. Information in this release is fact checked and produced on a best efforts basis and reviewed by a CFA. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at [email protected].
5. For any urgent concerns or inquiries, please contact us at [email protected].
6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to [email protected] for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider has, through Chartered Financial Analysts, only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

http://www.analystscorner.com

SOURCE Analysts' Corner